Tenofovir (all routes except local)

Large for gestational age (weight)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5134
R13387		 Floridia, 2018 Large by gestational age (birthweight > 90th) during pregnancy (anytime or not specified) cohort exposed to other treatment, sick Adjustment: No Control group: Abacavir/Lamivudine-based Exposed group: TDF/emtricitabine-based Indication: HIV 1.07 [0.56;2.02] 37/528   14/212 51 528
ref
S5211
R13519		 Malaba, 2017 Large for gestational age (weight > 90th percentile for gestational age) during pregnancy (anytime or not specified) prospective cohort unexposed, disease free Adjustment: No Control group: Unexposed, disease free Exposed group: TDF/emtricitabine-based Indication: HIV 0.71 [0.47;1.06] C 112/1,208   35/277 147 1,208
ref
Total 2 studies 0.80 [0.55;1.17] 198 1,736
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Floridia, 2018Floridia, 2018 1.07[0.56; 2.02]5152831%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Malaba, 2017Malaba, 2017 0.71[0.47; 1.06]1471,20869%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 12% 0.80[0.55; 1.17]1981,7360.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.80[0.55; 1.17]1981,73612%NAFloridia, 2018 Malaba, 2017 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.71[0.47; 1.06]1471,208 -NAMalaba, 2017 1 exposed to other treatment, sickexposed to other treatment, sick 1.07[0.56; 2.01]51528 -NAFloridia, 2018 1 Tags Adjustment   - No  - No 0.80[0.55; 1.17]1981,73612%NAFloridia, 2018 Malaba, 2017 2 Control group   - Abacavir/Lamivudine-based  - Abacavir/Lamivudine-based 1.07[0.56; 2.01]51528 -NAFloridia, 2018 1   - Unexposed, disease free  - Unexposed, disease free 0.71[0.47; 1.06]1471,208 -NAMalaba, 2017 1 Exposed group   - TDF/emtricitabine-based  - TDF/emtricitabine-based 0.80[0.55; 1.17]1981,73612%NAFloridia, 2018 Malaba, 2017 2 Indication   - HIV  - HIV 0.80[0.55; 1.17]1981,73612%NAFloridia, 2018 Malaba, 2017 2 All studiesAll studies 0.80[0.55; 1.17]1981,73612%NAFloridia, 2018 Malaba, 2017 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.71[0.47; 1.06]1471,208 -NAMalaba, 2017 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.07[0.56; 2.01]51528 -NAFloridia, 2018 10.510.01.0